Literature DB >> 22551032

Immunization strategies for Clostridium difficile infections.

Fabien Rebeaud1, Martin F Bachmann.   

Abstract

Clostridium difficile infection is a major cause of nosocomial disease in Western countries. The recent emergence of hypervirulent strains resistant to most antibiotics correlates with increasing disease incidence, severity and lethal outcomes. Current treatments rely on metronidazol and vancomycin, but the limited ability of these antibiotics to cure infection and prevent relapse highlights the need for new strategies. A better knowledge of the molecular mechanisms of the disease, the host immune response and identification of key virulence factors of Clostridium difficile now permits the development of new products specifically targeting the pathogen. Immune-based strategies relying on active vaccination or passive administration of antibody products are the focus of intense research and, today, the efficacy of monoclonal antibodies and of two vaccines are evaluated clinically. This review presents recent data, discusses the different strategies and highlights the challenges linked to the development of immunization strategies against this emerging threat.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551032     DOI: 10.1586/erv.12.18

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  11 in total

Review 1.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Use of surveillance data to identify target populations for Staphylococcus aureus vaccines and prevent surgical site infections: a pilot study.

Authors:  Marie-Paule Gustin; Marine Giard; Thomas Bénet; Philippe Vanhems
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.

Authors:  Yuanguo Wang; Shaohui Wang; Laurent Bouillaut; Chunhui Li; Zhibian Duan; Keshan Zhang; Xianghong Ju; Saul Tzipori; Abraham L Sonenshein; Xingmin Sun
Journal:  Infect Immun       Date:  2018-10-25       Impact factor: 3.441

4.  Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.

Authors:  Shaohui Wang; Duolong Zhu; Xingmin Sun
Journal:  Microbiol Spectr       Date:  2022-05-18

Review 5.  Translational Aspects of the Immunology of Clostridioides difficile Infection: Implications for Pediatric Populations.

Authors:  Larry K Kociolek; Joseph P Zackular; Tor Savidge
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 5.235

6.  Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.

Authors:  Maria R Romano; Rosanna Leuzzi; Emilia Cappelletti; Marta Tontini; Alberto Nilo; Daniela Proietti; Francesco Berti; Paolo Costantino; Roberto Adamo; Maria Scarselli
Journal:  Toxins (Basel)       Date:  2014-04-22       Impact factor: 4.546

7.  A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters.

Authors:  Yuan-Kai Wang; Ya-Xian Yan; Hyeun Bum Kim; Xianghong Ju; Song Zhao; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2015-06-02       Impact factor: 3.452

8.  Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B.

Authors:  Alexey Gribenko; Elena Severina; Maninder K Sidhu; Kathrin U Jansen; Bruce A Green; Yury V Matsuka
Journal:  Biochem Biophys Rep       Date:  2017-01-05

9.  Multivalent display of minimal Clostridium difficile glycan epitopes mimics antigenic properties of larger glycans.

Authors:  Felix Broecker; Jonas Hanske; Christopher E Martin; Ju Yuel Baek; Annette Wahlbrink; Felix Wojcik; Laura Hartmann; Christoph Rademacher; Chakkumkal Anish; Peter H Seeberger
Journal:  Nat Commun       Date:  2016-04-19       Impact factor: 14.919

Review 10.  A Review of the Safety and Efficacy of Vaccines as Prophylaxis for Clostridium difficile Infections.

Authors:  Mackenzie Henderson; Amanda Bragg; Germin Fahim; Monica Shah; Evelyn R Hermes-DeSantis
Journal:  Vaccines (Basel)       Date:  2017-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.